IOL Chemicals & Pharmaceuticals Ltd
IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1]
It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.[2]
- Market Cap ₹ 2,408 Cr.
- Current Price ₹ 410
- High / Low ₹ 538 / 331
- Stock P/E 20.2
- Book Value ₹ 274
- Dividend Yield 1.22 %
- ROCE 12.3 %
- ROE 8.68 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 17.5%
Cons
- The company has delivered a poor sales growth of 4.82% over past five years.
- Company has a low return on equity of 10.4% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
482 | 564 | 385 | 580 | 711 | 983 | 1,685 | 1,894 | 1,967 | 2,184 | 2,217 | 2,133 | 2,072 | |
392 | 468 | 373 | 529 | 608 | 863 | 1,276 | 1,321 | 1,375 | 1,927 | 1,990 | 1,901 | 1,863 | |
Operating Profit | 89 | 96 | 11 | 51 | 102 | 120 | 410 | 574 | 592 | 257 | 227 | 232 | 209 |
OPM % | 18% | 17% | 3% | 9% | 14% | 12% | 24% | 30% | 30% | 12% | 10% | 11% | 10% |
3 | 1 | 1 | 1 | 1 | 6 | 10 | 16 | 24 | 17 | 25 | 30 | 30 | |
Interest | 57 | 60 | 59 | 61 | 68 | 64 | 51 | 21 | 6 | 8 | 16 | 16 | 14 |
Depreciation | 31 | 32 | 29 | 30 | 30 | 30 | 32 | 36 | 39 | 43 | 46 | 63 | 65 |
Profit before tax | 3 | 5 | -75 | -39 | 6 | 31 | 336 | 533 | 571 | 223 | 189 | 183 | 160 |
Tax % | 46% | 35% | -12% | 4% | 21% | 12% | 30% | 32% | 22% | 26% | 26% | 26% | |
2 | 3 | -67 | -40 | 5 | 28 | 237 | 361 | 445 | 166 | 140 | 135 | 119 | |
EPS in Rs | 0.61 | 1.15 | -13.99 | -7.12 | 0.83 | 4.93 | 41.61 | 63.51 | 75.73 | 28.22 | 23.84 | 23.07 | 20.26 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 5% | 8% | 14% | 17% | 22% |
Compounded Sales Growth | |
---|---|
10 Years: | 14% |
5 Years: | 5% |
3 Years: | 3% |
TTM: | -6% |
Compounded Profit Growth | |
---|---|
10 Years: | 45% |
5 Years: | -11% |
3 Years: | -33% |
TTM: | -21% |
Stock Price CAGR | |
---|---|
10 Years: | 21% |
5 Years: | 15% |
3 Years: | -9% |
1 Year: | -9% |
Return on Equity | |
---|---|
10 Years: | 20% |
5 Years: | 21% |
3 Years: | 10% |
Last Year: | 9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 26 | 29 | 48 | 56 | 56 | 56 | 57 | 57 | 59 | 59 | 59 | 59 |
Reserves | 142 | 160 | 154 | 129 | 132 | 160 | 408 | 747 | 1,202 | 1,332 | 1,448 | 1,553 |
405 | 377 | 400 | 453 | 447 | 422 | 284 | 59 | 3 | 44 | 80 | 33 | |
154 | 175 | 100 | 135 | 182 | 214 | 193 | 306 | 347 | 526 | 434 | 600 | |
Total Liabilities | 727 | 741 | 702 | 772 | 817 | 852 | 942 | 1,170 | 1,610 | 1,960 | 2,021 | 2,244 |
430 | 411 | 403 | 400 | 374 | 406 | 412 | 469 | 512 | 561 | 751 | 933 | |
CWIP | 32 | 33 | 4 | 4 | 21 | 7 | 27 | 19 | 48 | 105 | 90 | 101 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 20 | 21 |
265 | 297 | 295 | 369 | 422 | 439 | 503 | 682 | 1,048 | 1,292 | 1,159 | 1,190 | |
Total Assets | 727 | 741 | 702 | 772 | 817 | 852 | 942 | 1,170 | 1,610 | 1,960 | 2,021 | 2,244 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
53 | 78 | -47 | 18 | 83 | 120 | 273 | 471 | 380 | 91 | 123 | 291 | |
-18 | -12 | -5 | -27 | -23 | -50 | -63 | -184 | -317 | -121 | -119 | -192 | |
-32 | -66 | 50 | 9 | -60 | -70 | -197 | -272 | -58 | -2 | -4 | -92 | |
Net Cash Flow | 3 | 1 | -2 | -0 | 1 | -1 | 13 | 15 | 4 | -31 | -0 | 7 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 27 | 32 | 31 | 55 | 58 | 54 | 43 | 52 | 56 | 79 | 83 | 81 |
Inventory Days | 199 | 190 | 279 | 201 | 201 | 109 | 66 | 64 | 98 | 95 | 77 | 111 |
Days Payable | 116 | 119 | 92 | 102 | 115 | 83 | 42 | 62 | 79 | 95 | 74 | 123 |
Cash Conversion Cycle | 110 | 103 | 218 | 154 | 144 | 80 | 67 | 55 | 74 | 79 | 86 | 69 |
Working Capital Days | 82 | 58 | 173 | 125 | 108 | 73 | 57 | 57 | 66 | 78 | 86 | 76 |
ROCE % | 11% | 11% | -3% | 4% | 12% | 15% | 56% | 69% | 54% | 18% | 14% | 12% |
Documents
Announcements
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
1d - Intimation of lost share certificates and request for duplicates.
-
Board Meeting Intimation for Notice Of The Board Meeting
1d - Board meeting to approve Q2 financial results.
-
Announcement under Regulation 30 (LODR)-Credit Rating
30 Oct - Reaffirmation of credit rating by CARE Ratings.
-
Board Meeting Outcome for Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015
28 Oct - Appointment of Ms Rajni Jha as Independent Director.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
28 Oct - Appointment of Ms Rajni Jha as Independent Director.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Aug 2024Transcript PPT REC
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
May 2023TranscriptNotesPPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Mar 2021Transcript PPT
-
Dec 2020Transcript PPT
-
Nov 2020TranscriptNotesPPT
Largest Producer of Ibuprofen
It is the largest producer of Ibuprofen (12000 TPA) and the only company worldwide being backward integrated with ~35% Global share. It is the largest producer of Ethyl Acetate at Single Location in India and also 2nd largest producer of Iso Butyl Benzene (IBB) with ~30% Global share. [1]